Silverarc Capital Management’s Yarrow Bioscience YARW Stock Holding History

Silverarc Capital Management’s Portfolio YARW Stock Details YARW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-1,536	Closed	-$144K	–	81
2024 Q3	$144K	Sell	1,536 -7,812	-84%	-$740K	0.03%	70
2024 Q2	$921K	Buy	9,348 +7,620	+441%	+$950K	0.22%	58
2024 Q1	$265K	Buy	+1,728	New	+$186K	0.07%	72
2021 Q1	–	Sell	-97	Closed	-$552K	–	102
2020 Q4	$552K	Buy	+97	New	+$610K	0.32%	69

Other funds holding YARW

CAM

Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACA

Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

EAM

Exome Asset Management New York $162M AUM 259.04% 1-Year Est. Return

UOC

UBS O'Connor Chicago, Illinois $3.76B AUM 62.41% 1-Year Est. Return

SSA

Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Silverarc Capital Management's YARW Position: Q4 2024 in Review

Silverarc Capital Management sold out of Yarrow Bioscience (YARW) in Q4 2024, closing a stake of 1,536 shares — an estimated $144K sold.

Silverarc Capital Management first reported a position in YARW in Q4 2020 and held it in 4 quarters. The position peaked at $921K in Q2 2024. 34 funds tracked by Wall St. Rank hold YARW as of Q4 2024.

Silverarc Capital Management reported no remaining Yarrow Bioscience position as of Q4 2024 after selling out during the quarter.
Silverarc Capital Management sold 1,536 Yarrow Bioscience shares in Q4 2024, an estimated $144K.
Silverarc Capital Management first reported a position in Yarrow Bioscience in Q4 2020 and held it in 4 quarters.
Silverarc Capital Management's Yarrow Bioscience position peaked at $921K in Q2 2024.
34 funds tracked by Wall St. Rank held Yarrow Bioscience as of Q4 2024.

Based on Silverarc Capital Management's 13F filing for Q4 2024, filed 14 Feb 2025.